Skip Navigation

European Heart Journal 1983 4(10):712-717;
Copyright © 1983 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by GWILT, D. J.
Right arrow Articles by REID, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GWILT, D. J.
Right arrow Articles by REID, D. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1983, by the European Society of Cardiology

Intravenous isosorbide dinitrate in acute left ventricular failure—a dose–response study

D. J. GWILT, M. PETRI and D. S. REID

Freeman Hospital, Newcastle upon Tyne and United Birmingham Hospitals England

Received 7 July 1981; revised 23 November 1982; .

Requests for reprints to: Dr D. J. Gwilt, Queen Elizabeth Medical Centre, Birmingham B15 2TH.

Abstract

The haemodynamic effects of intravenous isosorbide dinitrate (Cedocard) in patients with severe acute left ventricular failure have been assessed using incremental infusion rates from 50 to 800µmin–1. For most patients most of the fall in pulmonary arterial diastolic pressure occurred by 200µg min–1, with little further fall at higher doses. At 200µgmin–1 pulmonary arterial diastolic pressure fell from 29 to 23 mgHg (P<0.001), there was no significant change in cardiac index (1.9 to 2.0Lmin–1m–2) or heart rate (108 to 108 beats min–1). Despite high doses, no side effects were observed.

Intravenous isosorbide dinitrate is effective and safe in the management of acute severe left ventricular failure. In most patients an infusion rate of about 200µg min–1 produces optimal haemodynamic effects.

Key Words: Heart failure • therapy • isosorbide dinitrate


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.